

**PEOPLE**

Creative BioMolecules (Hopkinton, MA) has appointed **Carl M. Cohen** to the new position of vice president, research. Dr. Cohen joins Creative from St. Elizabeth's Medical Center in Boston, where he held the positions of associate chairman of the department of biomedical research and chief of the division of cellular and molecular biology. In addition, he is a professor in the departments of medicine, anatomy and cellular biology at Tufts University School of Medicine.

Allelix Biopharmaceuticals (Toronto, Ontario, Canada) has announced that **William W. Crouse** has been appointed to the board of directors. Mr. Crouse is managing director of HealthCare Ventures of Princeton, N.J., and was previously president of Ortho Diagnostic Systems and a vice president of Johnson & Johnson International.

LXR Biotechnology (Richmond, CA) has named **Shelli Geer** CFO, succeeding Mark Tomei, who remains as a director. Ms. Geer has been vice president of finance and administration since October 1996, and controller since September 1994. The company also named Neil Flanzraich a director. Mr. Flanzraich has been a shareholder and chairman of the life sciences group of the law firm Heller Ehrman White & McAuliffe since 1995.

PathoGenesis Corp. (Seattle, WA) has announced that **John L. Gordon** has been elected to its board of directors. He replaces Edward J. Mathias, a managing director of the Carlyle Group, who has resigned from the board. Dr. Gordon is chairman and founder of Quercus Management Ltd., and was previously director of research of British Biotech Ltd. from 1987 to 1994.

Gensia Sicor (San Diego, CA) has announced the resignation of president and CEO **David F. Hale**. Donald E. Panoz, chairman of the board of directors, will assume Mr. Hale's responsibilities on an interim basis. Mr. Hale will remain a member of the board of directors and has agreed to serve as a consultant to the company.

**Shirish Hirani** has been appointed vice president of program management for Dyax (Cambridge, MA). He previously served in the same capacity at ImmuLogic.

Celtrix Pharmaceuticals (Santa Clara, CA) has announced that **Donald D. Huffman** has joined the company as vice president, finance and administration, and CFO. He replaces Mary Anne Ribbi, who has left the company to

pursue other interests. Mr. Huffman was most recently vice president and CFO at EndoSonics Corp.

Sequus Pharmaceuticals (Menlo Park, CA) has announced the appointment of **Edward L. Jacobs** as senior vice president of commercial operations. Mr. Jacobs was most recently president and CEO of Trilex Pharmaceuticals.

Sequana Therapeutics (La Jolla, CA) has announced that **Steve Sugino** has been promoted to vice president of corporate development, with responsibility for Sequana's activities in corporate partnering, academic collaborations, joint ventures and strategic financial planning. Mr. Sugino joined Sequana in July 1995.

Aurora Biosciences (San Diego, CA) has announced the recent appointment of three new directors to its management team: **Kleanthis Xanthopoulos**, director, molecular biology and genomics; **Susan M. Cole**, director, business development and technical licensing; and **Angela Hartley**, director, corporate communications and investor relations. Dr. Xanthopoulos joins Aurora from the NIH, where he was a section head at the National Human Genome Research Institute. Dr. Cole was most recently at 3M Minnesota Mining and Manufacturing, where she launched a new business in drug development and biomedical research markets using strategic alliances. Ms. Hartley served as director, investor relations at Corvas International prior to joining Aurora.



**Alejandro Zaffaroni** has retired from the boards of ALZA Corp. (Palo Alto, CA) and Affymetrix (Santa Clara, CA). Dr. Zaffaroni founded ALZA in 1968, served as chairman and CEO from 1968 to 1987, and has

held the position of cochairman since 1987. In 1991, he founded Affymetrix. Ernest Mario, cochairman and CEO of ALZA since 1993, will become assume Dr. Zaffaroni's duties. In his honor, the board will create the position "Founder and Director Emeritus." Dr. Zaffaroni recently announced plans to expand the activities of the Zaffaroni Foundation, which will concentrate on issues such as understanding the role of education in nutrition and the role of genetics in depression and addictive disorders.

- Answers to quiz on p. 102
- (a) Announced retirement in November, as he approaches age 75; (b) acquired by Zeneca Seeds; (c) Howell retired and Seragen was delisted from NASDAQ; (d) Sold in divorce settlement; (e) Renamed the National Human Genome Research Institute, becoming the 18th institute of NIH; (f) Renamed Children's Beverage Group with mission to promote "BrainSlush," a "kid-friendly" iced drink product.
  - (a) The Sequana-Artis merger to form AxyS on November 3, according to accident-prone Sequana CEO, Kevin Kinsella; (b) NextStar's soleful chief scientific officer, Larry Gold; (c) Carl Feldbaum, president of the Biotechnology Industry Association; (d) The signing into law of the FDA Modernization and Accountability Act of 1997, according to PhRMA president Alan E. Holmer and Sidney M. Wolfe, director of Public Citizen's Health Research Group, respectively.
  - (a) Bio; (b) Gen; (c) Pharm; (d) Cyte; (e) Seq; (f) Neo; (g) Oxyrd; (h) Cal.
  4. a-2; b-4; c-1; d-6; e-8; f-10; g-3; h-5; i-9; j-7
  - (a) Surgen, which is forming a bank of DNA samples from patients with cardiovascular disease; (b) The Whitehead Consortium, which focuses on functional genomics; (c) Genos Biosciences, which is creating a bank of tumor DNA samples; (d) Helicon Therapeutics, which is developing therapeutics in the CNS area.
  6. (a) *S. pyogenes*—sequence published in 1996; the rest in 1997; (b) Gene, the cloned bull—the rest are transgenic animals; Polly from PPL, Tracy and Rosie from Genzyme Transgenics, Astrid from Inttran, and Herman from Pharming BV; (c) Geref, Ares-Serono's growth hormone-releasing hormone—the rest are growth hormones; (d) Aconex, Biogen's beta-interferon—the rest are alpha; (e) Liberty Link from Agreco—the rest are Monsanto products; (f) Millennium Biologicals—it is fictitious (at the moment). Cambridge-based Millennium is a genomics company; Millennium Biologix is a Canadian company (Kingston, ON) focusing on bone diseases.
  7. Greenpeace and the LK's Cooperative Bank created the world's first biodegradable credit card made from Biopol, Monsanto's poly-β-hydroxybutyrate polymer from *Alcaligenes eutrophus*.
  - (a) Sequana [Therapeutics]; (b) diaDeXus (c) Aquila [Biopharmaceutical]
  9. (a) Exogent; (b) Geniva; (c) Kinetic Pharmaceuticals; (d) OraPharma; (e) AdProTech.